Press Release

Mvine first with antibody test status prototype

3 August 2020

Mvine Limited announces today it has become the first company to deliver a completed project from the funding competition ‘Business-led innovation in response to global disruption’ run by UK Research and Innovation (UKRI). This competition attracted 8,500 applications and 800 companies were awarded a maximum of £50,000 each in response to the £40M announcement made by HM Government on 20 May 2020.

In just two calendar months, a full working prototype, with detailed solution design and architecture developed during this first phase of the project, has been delivered on time and exactly to budget.

Main areas of focus have been on developing a solution to enable the recognition of individuals with positive antibody tests for Covid-19 but which does not require extensive new infrastructure and which allows for widespread acceptance and access to the result of the test.

This is highly innovative because the solution does not require identification of individuals and no personal identifiable information is required or stored in this process.

At the point of testing for antibodies, a tokenised individual test result is bound to an individual’s enrolled facial biometric template to provide ready online and offline verification of test result.

The project has been monitored by Innovate UK.

Dr Ian Campbell, Executive Chair at Innovate UK, said: “Businesses from all over the UK have answered our call rapidly to meet the challenges we face today and in the future through the power of innovation. The ideas we have seen can truly make a significant impact on society, improve the lives of individuals, especially those in vulnerable groups and enable businesses to prosper in challenging circumstances.”

Frank Joshi, Director at Mvine, said: “Our vision is to improve public health and citizen privacy by using digital technology in a new and innovative way. This project does exactly that and perfectly showcases British technology at its best. Mvine with its partner iProov together delivered a fully working demonstrator which is ready to be used in the national interest,”

Andrew Bud, CEO at iProov, said: “Ensuring consumer trust, security and privacy is essential to the success of projects in this space. iProov enables all three. iProov’s Genuine Presence Assurance secures the link between the citizen and Mvine’s antibody test status solution in this project, which we think can make an important contribution to forming the nation’s response to the COVID-19 crisis.”

Back to Press

Get a demo